WHAT IS CLAIMED IS

- 1. A pharmaceutical composition for the prophylaxis or treatment of viral myocarditis, which comprises 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 2. A pharmaceutical composition for the prophylaxis or treatment of viral diseases induced by viral myocarditis, which comprises 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- 3. The pharmaceutical composition of claim 1 or claim 2,

 15 wherein the viral myocarditis and viral diseases induced by


 viral myocarditis are caused by RNA virus or hepatitis virus.
 - 4. The pharmaceutical composition of claim 3, wherein the RNA virus is orthomyxovirus or picornavirus.
- 5. The pharmaceutical composition of claim 2, wherein the viral disease is viral hepatitis (type A, type B, type C, type E, type G and type TTV), adenovirus infection, influenza, herpes infection, viral encephalitis, cytomegalovirus infection, viral enteritis or viral pericarditis.
- 6. A pharmaceutical composition for the amelioration or prophylaxis of viral cytotoxicity, which comprises 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable sait thereof, and a pharmaceutically acceptable carrier.
 - 7. A method for the prophylaxis or treatment of viral myocarditis, which comprises administering an effective amount

of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof.

- 8. A method for the prophylaxis or treatment of viral diseases induced by viral myocarditis, which comprises administering an effective amount of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof.
- 9. The method of claim 7 or claim 8, wherein the viral

 10 myocarditis and viral diseases induced by viral myocarditis are
 caused by RNA virus or hepatitis virus.
 - 10. The method of claim 9, wherein the RNA virus is orthomyxovirus or picornavirus.
- 11. The method of claim 8, wherein the viral disease is viral hepatitis (type A, type B, type C, type E, type G and type TTV), adenovirus infection, influenza, herpes infection, viral encephalitis, cytomegalovirus infection, viral enteritis or viral pericarditis.
- 12. A method for the amedioration or prophylaxis of viral cytotoxicity, which comprises administering an effective amount of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof.
- 13. Use of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof for the production of a pharmaceutical agent for the prophylaxis or treatment of viral myocarditis.
 - 14. Use of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof for the production of a pharmaceutical agent for the prophylaxis or

20



- 15. The use of claim 13 or claim 14, wherein the viral myocarditis and viral diseases induced by viral myocarditis are induced by RNA virus or hepatitis virus.
 - 16. The use of claim 15, wherein the RNA virus is orthomyxovirus or picornavirus.
- 10 17. The use of claim 14, wherein the viral disease is viral hepatitis (type A, type B, type C, type E, type G and type TTV), adenovirus infection, influenza, herpes infection, viral encephalitis, cytomegalovirus infection, viral enteritis or viral pericarditis.
 - 18. Use of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmacologically acceptable salt thereof for the production of a pharmaceutical agent for the amelioration or prophylaxis of yiral cytotoxicity.
- 19. A commercial package comprising the pharmaceutical composition of claim 1 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of viral myocarditis.
- 20. A commercial package comprising the pharmaceutical composition of claim 2 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the prophylaxis or treatment of viral diseases induced by viral myocarditis.
 - 21. The commercial package of claim 19 or claim 20, wherein the viral myocarditis and viral diseases induced by viral



- The commercial package of claim 21, wherein the RNA virus is orthomyxovirus or picornavirus.
- The commercial package of claim 20%, wherein the viral disease is viral hepatitis (type A, Lype B, type C, type E, type G and type TTV), adenovirus infection, influenza, herpes infection, viral encephalitis, cytomegalovirus infection, viral 10 enteritis or viral pericarditis
- 24. A commercial package comprising the pharmaceutical composition of claim 6/and a written matter associated therewith, the written matter stating that the pharmaceutical 15 composition can or/should be used for the amelioration or prophylaxis of viral cytotoxicity.